ICSC T/CACM1061—Guidelinesforqualityassessmentofpharmacoeconomicsevaluation 中發(fā)布T/CACMT/CACM1061—目前 引 概 前GB/T1.1《標準化工作導則第1部分：標準的結構和編寫》給出的規(guī)則起草。引T/CACMT/CACM1061—藥物經(jīng)濟學質(zhì)量評價價值PEERs525，56（A1，A2，21（B1，B2，52C15，362D3，51E3，822～4 E1-E1-E1-E2-E2-E3-E3-權重ABCDE若無條目“E3-13（完全符合）×6（條目數(shù)）“C8-1同貨幣類型轉(zhuǎn)換為同一年及同一種貨幣表達的成本”（研究時限超過1年時應在報“E3-1（60%≤報告總分＜75%，報告根據(jù)實際情況修改完善后具有一定的參考價值；T/CACMT/CACM1061—30123本效果分析A1-A2-研究背B1-B1-B1-研究目的及意B2-B2-C1-C1-C2-C2-C2-C3-C3-研究人群和亞C4-C4-干預措施及對C5-C5-C6-C6-C7-C7-C8-C8-健康產(chǎn)出指標C9-C9-測量和評估基于偏好的健康C10-C10-資源消耗和成C11-C11-C11-C11-C11-C12-C13-C13-C13-C13-數(shù)據(jù)處理及分C14-C14-C14-C15-C15-成本與健康產(chǎn)D1-D1-進行“增量成本/增量產(chǎn)D2-D2-D3-E1-E1-E1-E2-E2-E2-說明研究的資金來源和資助者在研究問題確定、研究設說明其他非資金支持者的情E3-E3-說明資助者在研究問題確T/CACMT/CACM1061—BergerML,SmithMD.HealthCareCost,Quality,andOutcomes[R].ISPORBookofTerms,ISPOR,2003.DraugalisJR,BoolrmanJL,LarsonLN,etal.In:CurrentConcepts.Pharmacoeconomics[R].Kalamazoo.Michigan;The1Comrany,1989.J],2011,22222023-J].(4):48-J].中國藥物應用與監(jiān)測,2005,2(1):1-4.[J]2010(24):1978-[J].2009,282)80-[J].2003,14(1)4-J(4):73-吳久鴻,趙緋麗,劉國恩.藥物經(jīng)濟學研究的質(zhì)量評價思考[C].南寧:中國藥學會(ChinesePharmaceuticalAssociation).20135J]2007,22(3):463-464.J2010,712)23-J].2004,15(1):28-31.2013J26(17):2308-J循證心血管醫(yī)學雜志,2014,6(3):252-254.J].價,2014,31(6):381-384.J房,2011,22(22):2019-2022.2012—2014學評價指南(2011J]201510812-5[J].海醫(yī)藥,2015,36(1):14-17.2009—2013J].2015,26(11):1441-2010J房,2013,24(26):2401-2404.[J].藥雜志,2015,40(10):2050-2053.2007—2011[J].研究,2013,32(1):39-41.J],2011,22222023-2003—2012[J].藥房,2014,25(10):865-869.[J]2006,25(8)458-J].雜志,2007,27(4):531-532.[J].2008,19(11):801-805.C]學會.2011年全國醫(yī)藥學術論壇交流會暨臨床藥學與藥學服務研究進展培訓班論文集,2011.[J].2014,28(5):536-541.J]學,2008,3(1):48-56.[J]2006,25(6)245-[J]2006,25(6)245-MaynardA.Economicevaluationtechniquesinhealthcare.ReinventingThewheel？[J].Pharmacoeconomics,1997,11(2):115-118.DrummondMF,StoddartGL,TorranceGW.Methodsfortheeconomice-valuationofhealtheareprogrames[J].Oxford:OxofrdUniversityPress,1987.JohnsonJA,FriesenE.ReassessingtherelevanceofpharmacoeconomicAnalysesinformularydecisions[J].Pharmacoeconomics,1998,13(5Pt1):479-485.GendusoLA,KotsanosJG.Reviewofhealtheconomicguidelinesintheformofregulations,principles,policiesandpositions[J].DrugInfJ,1996,(30):l003-l016.[J].藥,2006,4(4):16-19.[J].200221(6)21-J].2001,12(3):138-140.[M].DrummondMF,JeffersonTO.GuidelineforauthorandpeerreviewersofeconomicsubmissiontotheBMJ.TheBMJEconomicEvaluationWorkingParty[J].BMJ,1996,313(7052):275-283.D].J衛(wèi)生經(jīng)濟,2014,33(9):62-65.HusereauD,DrummondM,PetrouS,etal.Consol?idatedhealtheconomicevaluationreportingstan?dards(CHEERS)-explanationandelaboration:areportoftheISPORhealtheconomicevaluationpublicationguidelinesgoodreportingpracticestaskforce[J].Valuehealth,2013,16(2):231-250.ChiouCF,HayJW,WallaceJF,etal.Developmentandvalidationofagradingsystemforthequalityofcost-effec?tivenessstudies[J].MedCare,2003,41(1):32-OfmanJJ,SullivanSD,NeumannPJ,etal.Exam?iningthevalueandqualityofhealtheconomicanalyses:im?plicationsofutilizingtheQHES[J].Jmanagcarepharm,2003,9(1):53-61.DrummondMF,JeffersonTO.GuidelinesforauthorsandpeerreviewersofeconomicsubmissionstotheBMJeconomicevaluationworkingparty[J].BMJ,1996,313(7052):275-283.EversS,GoossensM,DeVetH,etal.Criterialistforassessmentofmethodologicalqualityofeconomicevaluations:Con?sensusonhealtheconomiccriteria[J].IntJTechnolAssessHealthCare,2005,21(2):240-245.PhilipsZ,BojkeL,SculpherM,etal.Goodpracticeguide?linesfordecision-an